Osteosarcoma

Certepetide

Certepetide, an investigational cyclic peptide designed to activate a novel uptake pathway that allows coadministered or tethered (i.e., covalently bound) anticancer drugs to penetrate solid tumours more effectively, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of osteosarcoma.